Replies to post #225235 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I think you are misreading all of this.

It would not be the first time.

[exwannabe]

Any info contained in that year-end filing is info from 2018, I do not think they can even include anything from 2019.

10K:

Between January 2019 and March 2019, the Company converted debt of approximately $2.0 million principal and $125,000 accrued interest into approximately 10.9 million shares of common stock at fair value of $2.8 million. The Company recorded an approximate $0.9 million debt extinguishment loss from the conversion.

In March 2019, the Company issued 3.0 million shares of common stock from warrants exercised for cash. The Company received $688,000 cash.

On the orriginal topic though, I agree with kabunishi. The statement about multi several months is from Nov and does not imply it is now current (in the present tense).

[anders2211]

In their Q1 report 2019 ending March 31 NWBO repeated

As previously reported, the Company is now moving forward with the several stages of work that are needed to reach completion of this trial. These include finalizing the Statistical Analysis Plan, conducting the final data collection, data validation and data lock, and then unblinding and analyzing the data. Each of these stages are multi-month processes, involving teams of outside experts as well as Company personnel. This work also involves various special circumstances such as a crossover trial design and the issue of pseudo-progression as previously reported. The Company’s projections, estimates and expectations are subject to material changes as the work proceeds.

So now no one can no longer claim NWBO meant to have only to state this in dec 2019...!

NWBO will not present top line at ASCO